Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Top Cited Papers
- 1 May 2007
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 132 (5) , 1672-1683
- https://doi.org/10.1053/j.gastro.2007.03.024
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Natalizumab Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- A meta-analysis of the placebo rates of remission and response in clinical trials of active crohn’s diseaseGastroenterology, 2004
- A Structural View of Integrin Activation and SignalingDevelopmental Cell, 2003
- Natalizumab for Active Crohn's DiseaseNew England Journal of Medicine, 2003
- α4Integrins as Therapeutic Targets in Autoimmune DiseaseNew England Journal of Medicine, 2003
- A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's diseaseGastroenterology, 2001
- The pathophysiologic role of alpha 4 integrins in vivo.Journal of Clinical Investigation, 1994
- Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel diseaseGastroenterology, 1994
- Validating the SF-36 health survey questionnaire: new outcome measure for primary care.BMJ, 1992
- Development of a Crohn's Disease Activity IndexGastroenterology, 1976